Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial.

Abstract

BACKGROUND:

Patients with peripheral artery disease (PAD) undergoing lower extremity revascularization (LER) are at high risk of major adverse limb and cardiovascular events. The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities) trial demonstrated that rivaroxaban 2.5 mg twice daily reduced first events by 15%. The benefit of rivaroxaban on total (first and subsequent) events in this population is unknown.

OBJECTIVES:

This study sought to evaluate the total burden of vascular events in patients with PAD after LER and the efficacy of low-dose rivaroxaban on total events.

METHODS:

VOYAGER PAD randomized patients with PAD undergoing LER to rivaroxaban 2.5 mg twice daily plus aspirin or aspirin alone. The primary endpoint was time to first event of acute limb ischemia, major amputation of a vascular cause, myocardial infarction, ischemic stroke, or cardiovascular death. The current analysis considered all events (first and subsequent) for components of the primary endpoint as well as additional vascular events including peripheral revascularizations and venous thromboembolism. HRs were estimated by marginal proportional hazards models.

RESULTS:

Among 6,564 randomized events, there were 4,714 total first and subsequent vascular events including 1,614 primary endpoint events and 3,100 other vascular events. Rivaroxaban reduced total primary endpoint events (HR: 0.86; 95% CI: 0.75-0.98; P = 0.02) and total vascular events (HR: 0.86; 95% CI: 0.79-0.95; P = 0.003). An estimated 4.4 primary and 12.5 vascular events per 100 participants were avoided with rivaroxaban over 3 years.

CONCLUSIONS:

Patients with symptomatic PAD who are undergoing LER have a high total event burden that is significantly reduced with rivaroxaban. Total event reduction may be a useful metric to quantify the efficacy of rivaroxaban in this setting. (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities [VOYAGER PAD]; NCT02504216).

• Authors: Rupert M Bauersachs, Michael Szarek, Marianne Brodmann, Ivan Gudz, Eike Sebastian Debus, Mark R Nehler, Sonia S Anand, Manesh R Patel, Connie N Hess, Warren H Capell, Kevin Rogers, Eva Muehlhofer, Lloyd P Haskell, Scott D Berkowitz, William R Hiatt, Marc P Bonaca, VOYAGER PAD Committees and Investigators
• Journal: Journal of the American College of Cardiology (J Am Coll Cardiol) Vol. 78 Issue 4 Pg. 317-326 (07 27 2021) ISSN: 1558-3597 [Electronic] United States
• PMID: 34010631 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021. Published by Elsevier Inc.

Chemical References

• Factor Xa Inhibitors
• Rivaroxaban

Topics

• Aged
• Dose-Response Relationship, Drug
• Drug Therapy, Combination
• Factor Xa Inhibitors (administration & dosage)
• Global Health
• Humans
• Incidence
• Ischemia (epidemiology, etiology, prevention & control)
• Lower Extremity (blood supply)
• Male
• Middle Aged
• Peripheral Arterial Disease (complications, therapy)
• Rivaroxaban (administration & dosage)
• Treatment Outcome
• Vascular Surgical Procedures (methods)